Nucleoside

Biosynth to Offer Complex Chemistry Solutions at Greater Scales Following Acquisition of VIO Chemicals

Retrieved on: 
Tuesday, December 19, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Chemicals, Plastics, Manufacturing, Chemistry, Acquisition, Chemical substance, Nucleoside, Carbohydrate, VIO, Fine chemical

Biosynth, a supplier of critical raw materials to the life science industry, is pleased to announce today that it has acquired VIO Chemicals, a Zurich-based company with leading chemical R&D expertise and a global network of large-scale manufacturing partners.

Key Points: 
  • Biosynth, a supplier of critical raw materials to the life science industry, is pleased to announce today that it has acquired VIO Chemicals, a Zurich-based company with leading chemical R&D expertise and a global network of large-scale manufacturing partners.
  • The acquisition will expand Biosynth’s ability to secure its customers’ supply chains by bringing greater flexibility in scales for complex chemical manufacturing, with expertise across carbohydrates, nucleosides, intermediates, and specialty excipients, among others.
  • CEO and President of Biosynth, Urs Spitz, was pleased to welcome Biosynth’s long-standing collaborator.
  • “VIO Chemicals has a long standing relationship with Biosynth and is an excellent addition to our flagship Complex Chemicals division.

Nobel prize in medicine awarded to mRNA pioneers – here's how their discovery was integral to COVID vaccine development

Retrieved on: 
Monday, October 2, 2023
Vaccine, BioNTech, Nobel Prize, DNA, University, Cell membrane, HIV, Guanine, Pseudouridine, Oxygen, Infection, COVID-19, Cancer, Lipid, Adenine, Physiology, Research, COVID, Cell, Zika virus, Messenger, Nucleoside, Cytosine, Uridine, Immune system, Viral, ARD International Music Competition, Mouse, Weissmann, Pfizer, Pharmaceutical industry

The rapid development of these vaccines changed the course of the pandemic, providing protection against the SARS-CoV-2 virus.

Key Points: 
  • The rapid development of these vaccines changed the course of the pandemic, providing protection against the SARS-CoV-2 virus.
  • Their discovery was not only integral to COVID-19 vaccine development, but may also lead to the development of many other therapies – such as vaccines for cancer.

Life’s work

    • It’s made in the body from our very own DNA in a process called translation.
    • DNA is our special encoded handbook of instructions for manufacturing proteins, which are the building blocks for material in the body.
    • The cells then make whatever protein they’ve been instructed to, such as haemoglobin for helping red blood cells carry oxygen around the body.
    • The researchers faced two major challenges as they began their work.
    • Karikó and Weissman’s research had successfully eliminated the obstacles that had previously stood in the way of using mRNA clinically.

COVID vaccines

    • Researchers had already been working on developing mRNA vaccines before the pandemic, such as a vaccine for Ebola that didn’t receive much commercial interest.
    • This produced a harmless COVID particle which our cells then replicated, allowing our bodies to protect us from severe COVID infections when it encountered the real virus.
    • Studies have also shown mRNA vaccines might be useful in treating certain types of cancer.

BioVie Issues Letter to Shareholders

Retrieved on: 
Tuesday, July 18, 2023
Insulin resistance, Methylation, Guanine, Enzyme, Genetic code, Hypercholesterolemia, Cytosine, Plasma, Protein, Patient, Sound, DNA methylation, American Diabetes Association, Environment, Antioxidant, Disease, Horváth, Diet, Hypertriglyceridemia, Genetics, Human, DVD, Thymine, Public key certificate, Ageing, Adenine, Brain, Gene expression, Dementia, Homeostasis, Nucleoside, Hypertension, Oxidative stress, DSM-IV codes, Map, Overweight, CSF, Diagnosis, CpG, Human Genome Project, Conference, Behavior, Genome, Cognition, Exercise, COPD, DNA, Dementia 13, Deficit spending, Biomarker, Cell, MCI, Downregulation and upregulation, ADAS, Letter, MMSE, Cell death, Phosphorylation, Inflammation, Neuron, DNaM, AD, Health, Gene, Medical imaging, Pharmaceutical industry, Vaccine, Illumina

Over 3,000 significant correlations were found linking reductions in DNA methylation of various CpGs and cognitive, biomarker and neuroimaging endpoints.

Key Points: 
  • Over 3,000 significant correlations were found linking reductions in DNA methylation of various CpGs and cognitive, biomarker and neuroimaging endpoints.
  • I have prepared this letter to shareholders to provide an update that synthesizes all the information that we have released and presented at recent medical conferences.
  • NE3107 reduced CSF phospho-tau levels by -1.66 pg/mL (p=0.0343) and the ratio of p-tau to amyloid beta 42 (Aβ42) by -0.0024 (p=0.0401).
  • P-tau and Aβ are traditional biomarkers of AD progression and have been the focus for AD researchers for decades.

L'Oréal, in Partnership with Cainiao Network, Microsoft (China), Bloomage Biotech, and Other Key Suppliers, Unveils 'Subtle Carbon, Not Subtle Action' Carbon Reduction Manifesto

Retrieved on: 
Thursday, June 15, 2023
Carbon, Carbon accounting, Beauty, Food, Partner, Biotechnology, Cosmetics, GHG, Dicarboxylic acid, Nucleoside, Future, Organization, Protein, Greenhouse gas, Peptide, CDP, Ecosystem, Tourism, Renewable energy, Microsoft, Lipstick

Given its substantial scale and wide-reaching consumer base, the consumer industry plays an instrumental role in this process.

Key Points: 
  • Given its substantial scale and wide-reaching consumer base, the consumer industry plays an instrumental role in this process.
  • As a pioneer in the beauty industry, L'Oréal aspires to join forces with stakeholders in the consumer industry to propel sustainable consumption.
  • L'Oréal North Asia, in concert with ten strategic suppliers, launched a "Subtle Carbon, Not Subtle Action" carbon reduction manifesto.
  • These ten strategic suppliers all participated in the CDP and Ecovodis ratings and agreed to join the carbon reduction actions advocated by L'Oréal.

HuidaGene Therapeutics Announces Publication of the World's First Guanine Base-Editor

Retrieved on: 
Thursday, May 18, 2023
SAB, CBQT-FM, DNA, Guanosine, Guanine, Gene editing, C. J. T. Thamotheram, Deamination, Nucleoside, National Science Review, Patent, Thymidine, CBE, Nature Biotechnology, Entrepreneurship, Cytidine deaminase, Therapy, Adenosine deaminase, Publishing, Vaccine

SHANGHAI and CLINTON, N.J., May 18, 2023 /PRNewswire/ -- HuidaGene Therapeutics (辉大基因; HuidaGene), a clinical-stage genome-editing company, today announced the online National Science Review published the comprehensive data from a study of the world's first DNA base editor converting G-to-Y, glycosylase-based guanine base editor (gGBE).

Key Points: 
  • SHANGHAI and CLINTON, N.J., May 18, 2023 /PRNewswire/ -- HuidaGene Therapeutics (辉大基因; HuidaGene), a clinical-stage genome-editing company, today announced the online National Science Review published the comprehensive data from a study of the world's first DNA base editor converting G-to-Y, glycosylase-based guanine base editor (gGBE).
  • Company has filed an international patent application for this base editor and owns the exclusive global rights to the underlying patent.
  • Current widely-used DNA base editors mainly integrate programmable DNA binding proteins (Cas9, Cas12, or TALE protein variants) with base deaminases (cytidine deaminase or adenosine deaminase variants).
  • The new class of engineered glycosylases base editors may further enrich the base editing tool, establish disease models, and develop gene editing therapies."

HuidaGene Therapeutics Announces Publication of the World's First Guanine Base-Editor

Retrieved on: 
Thursday, May 18, 2023
SAB, CBQT-FM, DNA, Guanosine, Guanine, Gene editing, C. J. T. Thamotheram, Deamination, Nucleoside, National Science Review, Patent, Thymidine, CBE, Nature Biotechnology, Entrepreneurship, Cytidine deaminase, Therapy, Adenosine deaminase, Publishing, Vaccine

SHANGHAI and CLINTON, N.J., May 18, 2023 /PRNewswire/ -- HuidaGene Therapeutics (辉大基因; HuidaGene), a clinical-stage genome-editing company, today announced the online National Science Review published the comprehensive data from a study of the world's first DNA base editor converting G-to-Y, glycosylase-based guanine base editor (gGBE).

Key Points: 
  • SHANGHAI and CLINTON, N.J., May 18, 2023 /PRNewswire/ -- HuidaGene Therapeutics (辉大基因; HuidaGene), a clinical-stage genome-editing company, today announced the online National Science Review published the comprehensive data from a study of the world's first DNA base editor converting G-to-Y, glycosylase-based guanine base editor (gGBE).
  • Company has filed an international patent application for this base editor and owns the exclusive global rights to the underlying patent.
  • Current widely-used DNA base editors mainly integrate programmable DNA binding proteins (Cas9, Cas12, or TALE protein variants) with base deaminases (cytidine deaminase or adenosine deaminase variants).
  • The new class of engineered glycosylases base editors may further enrich the base editing tool, establish disease models, and develop gene editing therapies."

Innovassynth and Actylis partner to address Nucleic Acid Supply Chain Vulnerabilities

Retrieved on: 
Thursday, May 4, 2023
Science, Research, Health, Chemicals, Plastics, Genetics, Logistics, Supply Chain Management, Transport, Manufacturing, GMP, Custom, DNA, Partnership, Process, Speciality chemicals, Medication, RNA, Chemistry, CDMO, N-Acetylgalactosamine, Partner, Materials science, LNA, R, Phosphoramidite, Organometallics, Fine chemical, Nucleoside

Innovassynth, India, is a Custom Development & Manufacturing Organization (CDMO) and a trusted partner to Pharma & Drug Discovery, Life Sciences, Diagnostics, and Material Science companies worldwide.

Key Points: 
  • Innovassynth, India, is a Custom Development & Manufacturing Organization (CDMO) and a trusted partner to Pharma & Drug Discovery, Life Sciences, Diagnostics, and Material Science companies worldwide.
  • Innovassynth offers end-to-end manufacturing and a transparent supply chain for Phosphoramidites and a variety of nucleic acid reagents, which is a compelling proposition to customers lacking supply chain diversity.
  • Actylis provides local and global distribution in the US and Europe through strategically located warehouses, supply chain and sales offices in over ten countries.
  • Due to its techno commercial expertise, global sales and distribution network, Actylis has emerged as the trusted partner of choice.

Telesis Bio Releases BioXp® Select mRNA Synthesis Kit to Expand the Utility, Speed, and Impact of Its Automated Synthetic Biology Workstation

Retrieved on: 
Thursday, February 16, 2023
DNA, Synthetic biology, Messenger, Guide, Workflow, NGS, CRISPR, Entrepreneurship, Doctor of Philosophy, Telesis, Nucleoside, Infection, SAN, Drug discovery, Vaccine

SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced the availability of its BioXp® Select mRNA Synthesis Kit .

Key Points: 
  • SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced the availability of its BioXp® Select mRNA Synthesis Kit .
  • This kit enables on-demand and automated synthesis of mRNA beginning from a BioXp customer’s own plasmid DNA, overnight and at the push of a button.
  • Last year, the company launched its first mRNA synthesis kit, named BioXp™ mRNA Synthesis Kit , which builds mRNA up to 1.8 kb in length starting from a DNA sequence as input.
  • As with the first commercially launched mRNA synthesis kit, this new BioXp mRNA synthesis kit will also incorporate the CleanCap® technology and provide options for modified nucleosides.

MAIA Biotechnology Advances New Telomere-Targeting Molecule Program

Retrieved on: 
Tuesday, January 17, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Molecule, Cell, MAIA, Death, DNA, Patient, Drug discovery, Nucleic acid, NYSE, Pharmaceutical industry, Nucleotide, Nucleoside

MAIA Biotechnology, Inc. (NYSE American: MAIA ) announced today the advancement of its Telomere-Targeting Molecule Program (“Project T3”).

Key Points: 
  • MAIA Biotechnology, Inc. (NYSE American: MAIA ) announced today the advancement of its Telomere-Targeting Molecule Program (“Project T3”).
  • MAIA is designing and evaluating multiple telomere-targeting compounds designed to modify the telomeric structure through the cancer cell - intrinsic telomerase activity - and thus cause the death of these cells.
  • MAIA also has filed a broad provisional patent application covering the composition of matter for the new telomere-targeting molecules in the fourth quarter of 2022.
  • “The discovery and preclinical advancement of these new telomere-targeting compounds represent the beginning of a significant new chapter for MAIA,” said Sergei Gryaznov, Ph.D., MAIA Chief Scientific Officer.

MAIA Biotechnology Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, November 9, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Forward-looking statement, IND, EORTC, Congress, NYSE, ESMO, Research and development, Expense, Oncology, Research, Hepatocellular carcinoma, Longevity, European Society for Medical Oncology, G&A, Nucleic acid, Large-cell lung carcinoma, R, HCC, View, Safety, Survival, Cancer, Ageing, Company, Triple, Patient, Biotechnology, Growth, NSCLC, Administration, Industry, MAIA, Fine chemical, Pharmaceutical industry, Nucleoside, Income, Nucleotide

MAIA Biotechnology, Inc. , (NYSE American: MAIA) (MAIA, the Company), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today reported financial results for the third quarter ended September 30, 2022, and provided a corporate update.

Key Points: 
  • MAIA Biotechnology, Inc. , (NYSE American: MAIA) (MAIA, the Company), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today reported financial results for the third quarter ended September 30, 2022, and provided a corporate update.
  • Research and Development (R&D) Expenses: R&D expenses were approximately $2.3 million for the quarter ended September 30, 2022, compared to approximately $1.1 million for the same quarter of 2021.
  • R&D expenses included approximately $0.2 million and $0.3 million of non-cash stock compensation expense in the third quarter 2022 and 2021, respectively.
  • In this release, unless the context requires otherwise, MAIA, Company, we, our, and us refers to MAIA Biotechnology, Inc. and its subsidiaries.